...
首页> 外文期刊>ESC Heart Failure >Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
【24h】

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study

机译:在急性心力衰竭患者期间改善了心脏病患者的心脏和静脉压力:超声心动图和生物标志物研究

获取原文

摘要

Aims Changes in echocardiographic parameters and biomarkers of cardiac and venous pressures or estimated plasma volume during hospitalization associated with decongestive treatments in acute heart failure (AHF) patients with either preserved left ventricular ejection fraction (LVEF) (HFPEF) or reduced LVEF (HFREF) are poorly assessed. Methods and results From the metabolic road to diastolic heart failure: diastolic heart failure (MEDIA‐DHF) study, 111 patients were included in this substudy: 77 AHF (43 HFPEF and 34 HFREF) and 34 non‐cardiac dyspnea patients. Echocardiographic measurements and blood samples were obtained within 4 h of presentation at the emergency department and before hospital discharge. In AHF patients, echocardiographic indices of cardiac and venous pressures, including inferior vena cava diameter [from 22 (16–24) mm to 13 (11–18) mm, P = 0.009], its respiratory variability [from 32 (8–44) % to 43 (29–70) %, P = 0.04], medial E/e' [from 21.1 (15.8–29.6) to 16.6 (11.7–24.3), P = 0.004], and E wave deceleration time [from 129 (105–156) ms to 166 (128–203) ms, P = 0.003], improved during hospitalization, similarly in HFPEF and HFREF patients. By contrast, no changes were seen in non‐cardiac dyspnea patients. In AHF patients, all plasma biomarkers of cardiac and venous pressures, namely B‐type natriuretic peptide [from 935 (514–2037) pg/mL to 308 (183–609) pg/mL, P 0.001], mid‐regional pro‐atrial natriuretic peptide [from 449 (274–653) pmol/L to 366 (242–549) pmol/L, P 0.001], and soluble CD‐146 levels [from 528 (406–654) ng/mL to 450 (374–529) ng/mL, P = 0.003], significantly decreased during hospitalization, similarly in HFPEF and HFREF patients. Echocardiographic parameters of cardiac chamber dimensions [left ventricular end‐diastolic volume: from 120 (76–140) mL to 118 (95–176) mL, P = 0.23] and cardiac index [from 2.1 (1.6–2.6) mL/min/m2 to 1.9 (1.4–2.4) mL/min/m2, P = 0.55] were unchanged in AHF patients, except tricuspid annular plane systolic excursion (TAPSE) that improved during hospitalization [from 16 (15–19) mm to 19 (17–21) mm, P = 0.04]. Estimated plasma volume increased in both AHF [from 4.8 (4.2–5.6) to 5.1 (4.4–5.8), P = 0.03] and non‐cardiac dyspnea patients (P = 0.01). Serum creatinine [from 1.18 (0.90–1.53) to 1.19 (0.86–1.70) mg/dL, P = 0.89] and creatinine‐based estimated glomerular filtration rate [from 59 (40–75) mL/min/1.73m2 to 56 (38–73) mL/min/1.73m2, P = 0.09] were similar, while plasma cystatin C [from 1.50 (1.20–2.27) mg/L to 1.78 (1.33–2.59) mg/L, P 0.001] and neutrophil gelatinase associated lipocalin (NGAL) [from 127 (95–260) ng/mL to 167 (104–263) ng/mL, P = 0.004] increased during hospitalization in AHF. Conclusions Echocardiographic parameters and plasma biomarkers of cardiac and venous pressures improved during AHF hospitalization in both acute HFPEF and HFREF patients, while cardiac chamber dimensions, cardiac output, and estimated plasma volume showed minimal changes.
机译:目的在于与急性心力衰竭(AHF)患者的减要性治疗相关左心室喷射分数(LVEF)(HFPEF)或减少的LVEF(HFREF)患者的住院期间,心脏和静脉压力或估计血浆体积的变化评估差。从代谢路径到舒张性心力衰竭的方法和结果:舒张性心力衰竭(媒体DHF)研究,111例患者包含在该替换中:77 AHF(43 HFPEF和34 HFREF)和34例非心脏病患者。在急诊部门和医院放电之前,在4小时内获得超声心动图测量和血液样本。在AHF患者中,心脏和静脉压力的超声心动图索引,包括下腔静脉直径[从22(16-24)mm至13(11-18)mm,p = 0.009],其呼吸变异性[来自32(8-44 )%〜43(29-70)%,p = 0.04],中介E / E'[从21.1(15.8-29.6)至16.6(11.7-24.3),p = 0.004]和E波减速时间[从129 (105-156)MS至166(128-203)MS,P = 0.003],在住院期间改善,同样在HFPEF和HFREF患者中。相比之下,在非心脏病患者中没有看到任何变化。在AHF患者中,所有心脏和静脉压力的血浆生物标志物,即B型利钠肽[从935(514-2037)pg / ml至308(183-609)pg / ml,p <0.001],中期专业 - 赤料肽[从449(274-653)pmol / l至366(242-549)pmol / l,p <0.001]和可溶性CD-146水平[从528(406-654)ng / ml至450 (374-529)Ng / ml,p = 0.003],住院期间显着降低,同样在HFPEF和HFREF患者中。心脏室尺寸的超声心动图参数[左心室舒张性体积:从120(76-140)ml至118(95-176)ml,p = 0.23]和心脏指数[来自2.1(1.6-2.6)ml / min /在AHF患者中,M2至1.9(1.4-2.4)mL / min / m2,p = 0.55]除了在住院期间改善的三尖瓣环形平面收缩偏移(TAPSE),除了16(15-19)mm至19(17 -21)mm,p = 0.04]。 AHF的估计血浆体积增加[从4.8(4.2-5.6)至5.1(4.4-5.8),p = 0.03]和非心脏病毒患者(P = 0.01)。血清肌酐[从1.18(0.90-1.53​​)至1.19(0.86-1.70)mg / dl,p = 0.89]和基于肌酐的估计肾小球过滤速率[从59(40-75)ml / min / 1.73m2至56( 38-73)ml / min / 1.73m2,p = 0.09],血浆胱抑素c [从1.50(1.20-2.27)mg / l至1.78(1.33-2.59)mg / l,p <0.001]和中性粒细胞在AHF的住院期间,明胶酶[来自127(95-260)Ng / ml至167(104-263)ng / ml,p = 0.004]的脂糖蛋白(Ngal)增加。结论在急性HFPEF和HFREF患者的AHF住院期间心脏和静脉压力的超声心动图参数和血浆生物标志物,而心房尺寸,心输出和估计血浆体积显示出最小的变化。
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号